Author:
Atabiekov Ihor,Hobeika Elie,Sheikh Ujalla,El Andaloussi Abdeljabar,Al-Hendy Ayman
Abstract
Premature ovarian insufficiency (POI) is a highly prevalent disorder, characterized by the development of menopause before the age of 40. Most cases are idiopathic; however, in some women the cause of this condition (e.g.; anticancer treatment, genetic disorders, and enzymatic defects) could be identified. Although hormone-replacement therapy, the principal therapeutic approach for POI, helps alleviate the related symptoms, this does not effectively solve the issue of fertility. Assisted reproductive techniques also lack efficacy in these women. Thus, an effective approach to manage patients with POI is highly warranted. Several mechanisms associated with POI have been identified, including the lack of function of the follicle-stimulating hormone (FSH) receptor, alterations in apoptosis control, mutations in Sal-like 4 genes, and thymulin or basonuclin-1 deficiency. The above mentioned may be good targets for gene therapy in order to correct defects leading to POI. The goal of this review is to summarize current experiences on POI studies that employed gene therapy, and to discuss possible future directions in this field.
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference85 articles.
1. International Menopause Societyhttp://www.imsociety.org/menopause_terminology.php
2. Incidence of Premature Ovarian Failure
3. Management of the Menopause;Rees,2009
4. Genes involved in human premature ovarian failure
5. The FMR1 premutation and reproduction
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献